Abbott Laboratories (ABT) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

ABT's EP business gains momentum as Volt adoption accelerates and new device launches expand its portfolio despite LAA market weakness.…

On November 16, 2026, we delve into the DCF analysis for Abbott Laboratories (ABT), a company that has seen a challenging year with its stock price reflecting a…

AlTi Global Inc. increased its position in shares of Abbott Laboratories (NYSE: ABT) by 114.9% during a recent quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional i…

Allworth Financial LP raised its holdings in Abbott Laboratories (NYSE: ABT) by 5.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 269,783…

ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.…

CenterBook Partners LP bought a new position in shares of Abbott Laboratories (NYSE: ABT) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional i…

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.…

ABT's UltiSynq lead combines conduction system pacing and defibrillation, with strong clinical trial results supporting its potential to expand the company's cardiac rhythm management portfolio.…

Allen Investment Management LLC cut its stake in shares of Abbott Laboratories (NYSE: ABT) by 45.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,000…

Ashton Thomas Private Wealth LLC boosted its stake in shares of Abbott Laboratories (NYSE: ABT) by 8.2% during a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). …

Associated Banc Corp acquired a new stake in Abbott Laboratories (NYSE: ABT) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired…

Heritage Investors Management Corp decreased its stake in Abbott Laboratories (NYSE: ABT) by 17.0% in a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The insti…

Abbott Laboratories (NYSE:ABT) reported positive clinical trial results for two investigational cardiovascular devices at the Transcatheter Cardiovascular Therapeutics conference in San Diego, demonstrating high procedur…

Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions; data show the device achieved hi…

SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary arteries and restore blood…

CROWN-MV trial will evaluate the safety and effectiveness of investigational Cephea mitral valve replacement device Abbott's Cephea is designed to provide a new, minimally invasive option for treating mitral valve diseas…

Powered by whole-genome sequencing and MAESTRO * technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit of detection below one part p…

Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing 1 Building on its leadership in colorectal cancer screening with the Cologuard …

Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42 Expands portfolio with key new product approvals ABBOTT P…

Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies The new Nutrition company will be a global leader in the rapidly growing healthy nutrition market, with a portfol…

New powder combines 30 grams of high‑quality protein to help build muscle tissue,† 5 grams of creatine monohydrate to support muscle recovery‡* and 3 grams of calcium HMB (beta-hydroxy-beta-methylbutyrate) to help preser…

For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP can signal worsening heart …

ABBOTT PARK, Ill., Sept. 30, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2026 financial results on Wednesday, Oct. 21, before the market opens.…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Jan 25. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

